ACS chemical neuroscience molecule spotlight on semagacestat (ly450139)

Research output: Contribution to journalShort surveypeer-review

10 Scopus citations


Semagacestat (LY450139) is a novel ?-secretase inhibitor currently in late-stage development by Eli Lilly and Company as a potential treatment for Alzheimer's disease (AD). Semagacestat is currently being studied in two phase III clinical trials.

Original languageEnglish (US)
Pages (from-to)533-534
Number of pages2
JournalACS Chemical Neuroscience
Issue number8
StatePublished - Aug 18 2010
Externally publishedYes


  • AD
  • Alzheimer's disease
  • Gamma-secretase
  • LY450139
  • neurodegeneration
  • semagacestat

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology


Dive into the research topics of 'ACS chemical neuroscience molecule spotlight on semagacestat (ly450139)'. Together they form a unique fingerprint.

Cite this